Condition
Calcific Aortic Valve Disease
Total Trials
5
Recruiting
0
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Not Yet Recruiting1
Unknown1
Completed1
Active Not Recruiting1
Suspended1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07565077Active Not RecruitingPrimary
Impact of TAVI on the Gut Microbiota and Its Metabolites
NCT05143177Phase 2SuspendedPrimary
A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)
NCT07091136Phase 2Not Yet RecruitingPrimary
Exploration of Manidipine to Reverse Aortic Valve Calcification
NCT04055883Phase 2CompletedPrimary
Clinical Study to Evaluate Efficacy and Safety of DA-1229 in Patients With CAVD
NCT04312139UnknownPrimary
Serum and Cellular Biomarkers for Aortic Valve Stenosis
Showing all 5 trials